PIR and neoplasm: In non-small cell lung carcinoma, piR-651 increased the expression of Cyclin D1 and CDK4 to promote tumor progression [50], while piR-55490 inhibited cell proliferation in lung cancer cells by targeting the 3′ UTR (untranslated region) of mTOR mRNA [51].